Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Fineline Cube May 20, 2026
Company Drug

Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP

Fineline Cube Jun 19, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the...

Company Drug

Fosun Pharma’s Fumaining Launches Clinically for Rare Disease Treatment in China

Fineline Cube Jun 19, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd.’s (HKG: 2196, SHA: 600196) in-house developed Category 1 drug...

Drug Policy / Regulatory

FDA Launches Commissioner’s National Priority Voucher Program for Accelerated Drug Reviews

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) this week announced the launch of the Commissioner’s...

Company Drug

Hengrui Pharma’s Ruitanning Enters Clinical Use for Chemo-Induced Nausea and Vomiting

Fineline Cube Jun 19, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the prescription of its Category 1...

Company Drug

Merck’s Clesrovimab Gears Up for Priority Review in China for RSV Prevention

Fineline Cube Jun 19, 2025

China’s Center for Drug Evaluation (CDE) website indicates that US giant Merck, Sharp & Dohme’s...

Company Drug

Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes

Fineline Cube Jun 18, 2025

Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...

Company Medical Device

Allgens Medical’s SkuHeal Artificial Bone Repair Material Gains Vietnam Marketing Approval

Fineline Cube Jun 18, 2025

Beijing-based regenerative medicine materials and implantable device maker Allgens Medical Technology Co., Ltd (SHA: 688613)...

Company Drug

Clover Biopharmaceuticals Completes Enrollment for Phase I Trial of RSV + hMPV Combination Vaccines

Fineline Cube Jun 18, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the completion of enrollment for the first participants...

Company Deals

Shanghai Henlius Biotech Partners with Shanghai Chest Hospital for Clinical Research and Talent Development

Fineline Cube Jun 18, 2025

China’s Shanghai Henlius Biotech Inc., (HKG: 2696) this week entered into a strategic collaboration agreement...

Company Drug

RemeGen’s Telitacicept Receives Orphan Drug Designation for Myasthenia Gravis in Europe

Fineline Cube Jun 18, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced that it has received orphan drug...

Company Drug

Yunnan Baiyao’s JZ-14 Gets NMPA Clinical Clearance for Ulcerative Colitis Trial

Fineline Cube Jun 18, 2025

Kunming-based Yunnan Baiyao Group Co., Ltd (SHE: 000538), traditionally known for Chinese medicine, announced clinical...

Company Drug

Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease

Fineline Cube Jun 18, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG005 and ZG006 Combination Trial in Advanced Cancers

Fineline Cube Jun 18, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Medical Device

Mindray Bio-Medical Expands North American Warehouse to Enhance Operational Efficiency

Fineline Cube Jun 18, 2025

China-based Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) announced the groundbreaking of its North...

Company

GSK Launches ‘Linked by Lupus’ Initiative to Support Lupus Care with $1M Funding

Fineline Cube Jun 18, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the launch of the Linked by Lupus:...

Company Drug

Bayer Files NDA for Gadoquatrane, Aiming to Offer Lowest-Dose GBCA in the U.S.

Fineline Cube Jun 18, 2025

Germany-based Bayer AG (ETR: BAYN) announced that it has made a New Drug Application (NDA)...

Company Deals

EpimAb Biotherapeutics Submits Hong Kong IPO Application as Biotech Expands

Fineline Cube Jun 18, 2025

Shanghai-based biotech EpimAb Biotherapeutics, Inc. has submitted a main board listing application to the Hong...

Company Drug

Sinocelltech Gains NMPA Clearance for SCTB39-1 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 18, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...

Company Drug

Santen’s Ryjunea Gets EU Approval to Slow Myopia Progression in Children

Fineline Cube Jun 18, 2025

Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from the European...

Company

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

Fineline Cube Jun 18, 2025

Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...

Posts pagination

1 … 144 145 146 … 669

Recent updates

  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
  • Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets
  • Shanghai ZJ Bio-Tech Secures International Approvals for Molecular Diagnostic Platforms in Netherlands and Mexico
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Company

China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease

Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.